The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009, an investigational oral therapy being developed by Inhibikase Therapeutics to slow or stop disease progression.
“We are pleased to begin dosing patients in our Phase 1b study,” Milton Werner, PhD, Inhibikase‘s president and CEO, said in a press release.
Looks promising. Thank you for sharing.
It's moving to a Phase 2 randomized, double-blind, 12-week dosing trial assessing safety & tolerability in untreated
New Hope.. Company extract
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
Phase 3 Positive Topline Results for Tavapadon 
British hospital becomes first in the world to trial wearable tech for Parkinson’s patients
Potential Parkinson’s Treatment, CDNF, Shows Safety and Tolerability at One Year
